[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Donald Basel\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100264949",false,"NCT02728388","Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II","Topical Photodynamic Therapy (PDT) With Levulan® Kerastick® for Benign Dermal Neurofibromas Phase II","Inclusion Criteria:\n\n1. Patient is 14 years or older.\n2. Diagnosed NF1, determined by American Academy of Neurology Guidelines (see Diagnosis section).\n3. Tumor Location: cutaneous, trunk, or limbs only.\n4. Tumor Type: superficial dermal neurofibromas ≤4mm deep.\n5. Patient has provided written informed consent.\n6. Patient is willing to and can comply with study follow-up requirements.\n7. Absence of any other malignancy.\n\nExclusion Criteria:\n\n1. Life expectancy less than 3 years.\n2. Pregnancy.\n3. Cutaneous photosensitivity to the wavelengths used to active PDT.\n4. A diagnosis of porphyria.\n5. Allergy to aminolevulinic acid or any of the topical solution vehicle components.\n6. Previous chemotherapy within 6 weeks of proposed PDT.\n7. Other concurrent tumor therapy.","ALL","14 Years","30 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The investigators wish to determine the time to disease progression for benign neurofibromas treated with Levulan Kerastick topical photosensitizer and red light photodynamic therapy (PDT) in patients with neurofibromatosis type 1 (NF1).\n\nThe investigators also wish to measure tumor size for control and treatment tumors in order to gain insights into tumor growth rates.",[26],"NEUROFIBROMATOSIS 1",[28,29,30],"NF1","Neurofibroma","Neurofibromatosis Type 1","RECRUITING","2025-05-05",{"date":34,"type":35},"2025-05-08","ACTUAL",{"date":37,"type":35},"2016-08",{"date":39,"type":20},"2025-12",{"name":41,"class":42},"Donald Basel","OTHER",""]